Top

BMC Neurology

Published in:

Open Access 01-12-2021 | Parkinson's Disease | Research article

Social listening – revealing Parkinson’s disease over day and night

Authors: Hui Zhang, Fanwen Meng, Xingyu Li, Yali Ning, Meng Cai

Published in: BMC Neurology | Issue 1/2021

Abstract

Background

Nocturnal symptoms in Parkinson’s disease are often treated after management of daytime manifestations. In order to better understand the unmet needs of nocturnal symptoms management, we analyzed the characteristics and burden of nocturnal symptoms from patients’ perspectives and explored their changes over time. Overall symptoms (occurring at day or night) were collected to compare whether the unmet needs related to nocturnal symptoms and to overall symptoms are different.

Methods

We used a Social Listening big-data technique to analyze large amounts of Parkinson’s disease symptoms in dialogues available from social media platforms in 2016 to 2018. These symptoms were classified as either overall symptoms or nocturnal symptoms. We used share of voice (SOV) of symptoms as a proportion of total dialogues per year to reflect the characteristics of symptoms. Negative sentiment score of symptoms was analyzed to find out their related burden.

Results

We found the SOV for overall motor symptoms was 79% and had not increased between 2016 and 2018 (79%, p = 0.5). The SOV for non-motor symptoms was 69% and had grown by 7% in 2018 (p < 0.01). The SOV for motor complications was 9% and had increased by 6% in 2018 (p < 0.01). The SOV of motor symptoms was larger than non-motor symptoms and motor complications (p < 0.01). The SOV of non-motor symptoms was larger than motor complications (p < 0.01). For nocturnal symptoms, 45% of the analyzed PD population reported nocturnal symptoms in 2018, growing by 6% (p < 0.01). The SOV for nocturnal-occurring motor symptoms was higher than most non-motor symptoms. However, non-motor symptoms had the higher increases and evoked higher negative sentiment regardless of whether they occurred during the day or night. For symptoms that can occur at either day or night, each nocturnal symptom was rated with a higher negative sentiment score than the same symptom during the day.

Conclusions

The growing SOV and the greater negative sentiment of nocturnal symptoms suggest management of nocturnal symptoms is an unmet need of patients. A greater emphasis on detecting and treating nocturnal symptoms with 24-h care is encouraged.

Available only for authorised users

Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5. https://doi.org/10.1007/s00702-017-1686-y.CrossRefPubMed

Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinson’s disease. J Neurol. 2008;255(Suppl 5):18–32. https://doi.org/10.1007/s00415-008-5004-3.CrossRefPubMed

Ma C-L, Su L, Xie J-J, et al. The prevalence and incidence of Parkinson’s disease in China: a systematic review and meta-analysis. J Neural Transm. 2013;121(2):123–34. https://doi.org/10.1007/s00702-013-1092-z.CrossRefPubMed

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601. https://doi.org/10.1002/mds.26424.CrossRefPubMed

Bhidayasiri R, Mekawichai P, Jitkritsadakul O, et al. Nocturnal journey of body and mind in Parkinson’s disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. J Neural Transm. 2014;121(S1):59–68. https://doi.org/10.1007/s00702-014-1199-x.CrossRef

Shulman L, Taback R, Rabinstein A, et al. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8(3):193–7. https://doi.org/10.1016/s1353-8020(01)00015-3.CrossRefPubMed

Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11(6):512–9. https://doi.org/10.1097/00002826-198812000-00004.

Trenkwalder C, Kohnen R, Hogl B, et al. Parkinson’s disease sleep scale – validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644–52. https://doi.org/10.1002/mds.23476.CrossRefPubMed

Stocchi F, Coletti C, Bonassi S, et al. Early morning OFF and levodopa dose failures in PD patients attending a routine clinical appointment using time to ON questionnaire. Eur J Neurol. 2018. https://doi.org/10.1111/ene.13895.

10.

Louter M, Munneke M, Bloem BR, et al. Nocturnal Hypokinesia and sleep quality in Parkinson’s disease. J Am Geriatr Soc. 2012;60(6):1104–8. https://doi.org/10.1111/j.1532-5415.2012.03966.x.CrossRefPubMed

11.

Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406. https://doi.org/10.1002/mds.23462.CrossRefPubMed

12.

Bhidayasiri R, Sringean J, Trenkwalder C. Mastering nocturnal jigsaws in Parkinson’s disease: a dusk-to-dawn review of night-time symptoms. J Neural Transm. 2020;127:763–77. https://doi.org/10.1007/s00702-020-02170-6.CrossRefPubMed

13.

Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25(15):2493–500. https://doi.org/10.1002/mds.23394.CrossRefPubMed

14.

Pomputius A. Can you hear me now? Social listening as a strategy for understanding user needs. Med Ref Serv Q. 2019;38(2):181–6. https://doi.org/10.1080/02763869.2019.1588042.CrossRefPubMed

15.

Python Software Foundation. Python Language Reference, version 3.6. Available at http://www.python.org.

16.

Devlin J, Chang M-W, Lee K, et al. BERT: pre-training of deep bidirectional transformers for language understanding; 2019. https://arxiv.org/abs/1810.04805 [cs.CL].

17.

Hochreiter S, Schmidhuber J. Long short-term memory. Neural Comput. 1997;9(8):1735–80. https://doi.org/10.1162/neco.1997.9.8.1735.

18.

Lafferty J, McCallum A, Pereira FCN. Conditional random fields: probabilistic models for segmenting and labeling sequence data. In: Proceedings of the 18th international conference on machine learning 2001; 2001. p. 282–9.

19.

Hatano T, Kubo S-I, Shimo Y, et al. Unmet needs of patients with Parkinson’s disease: interview survey of patients and caregivers. J Int Med Res. 2009;37(3):717–26. https://doi.org/10.1177/147323000903700315.CrossRefPubMed

20.

Liu C-F, Wang T, Zhan S-Q, et al. Management recommendations on sleep disturbance of patients with Parkinson's disease. Chin Med J (Engl). 2018;131(24):2976–85. https://doi.org/10.4103/0366-6999.247210.CrossRef

21.

Chen W, Xu Z-M, Wang G, et al. Non-motor symptoms of Parkinson’s disease in China: a review of the literature. Parkinsonism Relat Disord. 2012;18(5):446–52. https://doi.org/10.1016/j.parkreldis.2012.02.002.CrossRefPubMed

22.

Stocchi F, Stirpe P. The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. J Neural Transm. 2014;121(S1):79–83. https://doi.org/10.1007/s00702-014-1259-2.CrossRef

23.

Rodríguez-Violante M, Ospina-Garcia N, Davila-Avila NM, et al. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson’s disease. Arq Neuropsiquiatr. 2018;76(8):517–21. https://doi.org/10.1590/0004-282X20180074.CrossRefPubMed

24.

Kianirad Y, Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16(4):34. https://doi.org/10.1007/s11910-016-0635-8.CrossRefPubMed

25.

Chaudhuri KR, Bhidayasiri R, van Laar T. Unmet needs in Parkinson’s disease: new horizons in a changing landscape. Parkinsonism Relat Disord. 2016;33:S2–8. https://doi.org/10.1016/j.parkreldis.2016.11.018.CrossRefPubMed

26.

Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019. https://doi.org/10.1002/mds.27602.

27.

Sringean J, Taechalertpaisarn P, Thanawattano C, et al. How well do Parkinson’s disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. Parkinsonism Relat Disord. 2016;23:10–6. https://doi.org/10.1016/j.parkreldis.2015.11.003.CrossRefPubMed

28.

Xue F, Wang F-Y, Mao C-J, et al. Analysis of nocturnal hypokinesia and sleep quality in Parkinson’s disease. J Clin Neurosci. 2018;54:96–101. https://doi.org/10.1016/j.jocn.2018.06.016.CrossRefPubMed

29.

Pahwa R, Bergquist F, Horne M, et al. Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the personal KinetiGraph®. J Clin Mov Disord. 2020;7:5. https://doi.org/10.1186/s40734-020-00087-6.CrossRefPubMedPubMedCentral

30.

Tang Y, Yang K, Zhao J, et al. Evidence of repurposing drugs and identifying contraindications from real world study in Parkinson’s disease. ACS Chem Nerosci. 2019. https://doi.org/10.1021/acschemneuro.8b00456.

31.

Pellicano C, Benincasa D, Giovannelli M, et al. Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study. Neurol Res. 2009;31(1):74–6. https://doi.org/10.1179/174313208X338052.CrossRefPubMed

32.

Panisset M, Stril JL, Belanger M, et al. Open-label study of sleep disturbances in patients with Parkinson’s disease treated with Rasagiline. Can J Neurol Sci. 2016;43(6):809–14. https://doi.org/10.1017/cjn.2016.289.CrossRefPubMed

33.

Shrempf W, Fauser M, Wienecke M, et al. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson’s disease: a double-blind, baseline-controlled trial. Eur J Neurol. 2018;25(4):672–9. https://doi.org/10.1111/ene.13567.CrossRef

34.

Wang L, Li J, Chen J. Levodopa-Carbidopa intestinal gel in Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2018;9:620. https://doi.org/10.3389/fneur.2018.00620.CrossRefPubMedPubMedCentral

35.

Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9. https://doi.org/10.1002/mds.23441.CrossRefPubMed

36.

Trenkwalder C, Kies B, Dioszeghy P, et al. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia. 2012;2(2):79–85. https://doi.org/10.1016/j.baga.2012.05.009.CrossRef

37.

Wang Y, Yang Y, Wu H, et al. Effects of rotigotine on REM sleep behavior disorder in Parkinson disease. J Clin Sleep Med. 2016;12(1403):1409. https://doi.org/10.5664/jcsm.6200.CrossRef

38.

Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early PARKINSON’S disease: a randomized, double blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398–404. https://doi.org/10.1002/mds.21741.CrossRefPubMed

39.

Pham DQ, Nogid A. Rotigotine transdermal system for the treatment of Parkinson’s disease. Clin Ther. 2008;30:813–24. https://doi.org/10.1016/j.clinthera.2008.05.007.CrossRefPubMed

40.

Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018;12:2017–24. https://doi.org/10.2147/DDDT.S160300.CrossRefPubMedPubMedCentral

41.

Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012;19(1):105–13. https://doi.org/10.1111/j.1468-1331.2011.03442.x.CrossRefPubMed

42.

Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24:1468–74. https://doi.org/10.1002/mds.22596.CrossRefPubMed

43.

Timpka J, Henriksen T, Odin P. Non-oral continuous drug delivery techniques in Parkinson’s disease: for whom, when, and how? Mov Disord Clin Pract. 2016;3(3):221–9. https://doi.org/10.1002/mdc3.12303.CrossRefPubMedPubMedCentral

44.

Krack P, Volkmann J, Tinkhauser G, et al. Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord. 2019. https://doi.org/10.1002/mds.27860.

45.

Beitz JM. Parkinson's disease: a review. Front Biosci (Schol Ed). 2014;6:65–74. https://doi.org/10.2741/s415.

46.

Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for health-related research involving humans; 2016. https://cioms.ch/publications/product/international-ethical-guidelines-for-health-related-research-involving-humans/.

Title: Social listening – revealing Parkinson’s disease over day and night
Authors: Hui Zhang
Fanwen Meng
Xingyu Li
Yali Ning
Meng Cai
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Parkinson's Disease
Published in: BMC Neurology / Issue 1/2021
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-02024-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Social listening – revealing Parkinson’s disease over day and night

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry

Evaluation of the response to electric pulp testing in multiple sclerosis patients without a history of trigeminal neuralgia: a case-control study

Clinical features and outcome of Guillain–Barre syndrome in Saudi Arabia: a multicenter, retrospective study

The parameters of gait analysis related to ambulatory and balance functions in hemiplegic stroke patients: a gait analysis study

FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide

Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction